Business Description
Tiziana Life Sciences Ltd
NAICS : 541714
SIC : 2834
ISIN : BMG889121031
Share Class Description:
TLSA: Ordinary SharesTotal Employee Number:
10Description
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.79 | |||||
Equity-to-Asset | 0.01 | |||||
Debt-to-Equity | 8.77 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.7 | |||||
3-Year EPS without NRI Growth Rate | -9.1 | |||||
3-Year FCF Growth Rate | 17.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.04 | |||||
9-Day RSI | 53.53 | |||||
14-Day RSI | 51.2 | |||||
3-1 Month Momentum % | -3.94 | |||||
6-1 Month Momentum % | -17.57 | |||||
12-1 Month Momentum % | -18.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.76 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | -6.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -419.27 | |||||
ROA % | -140.42 | |||||
ROIC % | -547.32 | |||||
3-Year ROIIC % | -479.21 | |||||
ROC (Joel Greenblatt) % | -6607.54 | |||||
ROCE % | -411.56 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -8.65 | |||||
EV-to-EBITDA | -8.76 | |||||
EV-to-FCF | -12.38 | |||||
Earnings Yield (Greenblatt) % | -11.56 | |||||
FCF Yield % | -7.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TLSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tiziana Life Sciences Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.16 | ||
| Beta | 0.5393 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.32 | ||
| Volatility % | 78.52 | ||
| 14-Day RSI | 51.2 | ||
| 14-Day ATR ($) | 0.105974 | ||
| 20-Day SMA ($) | 1.1765 | ||
| 12-1 Month Momentum % | -18.12 | ||
| 52-Week Range ($) | 1.04 - 2.6 | ||
| Shares Outstanding (Mil) | 127.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tiziana Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tiziana Life Sciences Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-16 08:30 | In 161 days | ||
| Second quarter earnings results for 2026 | 2026-10-02 | In 85 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 10:30 | 1.18 (-11.94%) | ||
| Annual report for 2025 | 2026-05-01 | 1.28 (+1.59%) | ||
| General meeting for 2025 | 2025-12-16 08:30 | 1.59 (-11.17%) | ||
| Second quarter earnings results for 2025 | 2025-10-03 | 2.00 (+2.56%) | ||
| Annual report for 2024 | 2025-05-06 | 1.22 (-3.17%) | ||
| 37th Annual Roth Conference | 2025-03-18 15:00 | 1.55 (-3.73%) | ||
| General meeting for 2024 | 2024-12-12 08:30 | 0.95 (-1.30%) | ||
| Second quarter earnings results for 2024 | 2024-10-18 | 0.90 (+2.99%) |
Show
Entries
Tiziana Life Sciences Ltd Frequently Asked Questions
What is Tiziana Life Sciences Ltd(TLSA)'s stock price today?
The current price of TLSA is $1.28. The 52 week high of TLSA is $2.60 and 52 week low is $1.04.
When is next earnings date of Tiziana Life Sciences Ltd(TLSA)?
The next earnings date of Tiziana Life Sciences Ltd(TLSA) is 2026-10-02 Est..
Does Tiziana Life Sciences Ltd(TLSA) pay dividends? If so, how much?
Tiziana Life Sciences Ltd(TLSA) does not pay dividend.
Guru Commentaries on NAS:TLSA
No articles.
Press Release
Articles on Tiziana Life Sciences Ltd
Headlines
See More- 1
Jun 15, 2026
Tiziana Life Sciences executive chairman buys 15,000 common shares
Seeking Alpha • 6:35am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers